HLB's Riboceranib + Camrelizumab Shows Consistent Efficacy Across Ages in CARES-310 uHCC Trial
In the global Phase 3 CARES-310 study, HLB's riboceranib‑camrelizumab combo achieved a median overall survival of 21.5 months in patients under 50, outperforming sorafenib's 15.2 months, with consistent benefit across age groups.
3 min read
AbbVie, Genmab report positive Phase 3 combo trial of Epkinly after monotherapy setback
A Phase 3 combination trial of AbbVie and Genmab’s Epkinly showed positive results, restoring confidence after a recent second‑line monotherapy failure in diffuse large B‑cell lymphoma.